add-on pioglitazone + add-on sulphonylurea
ApprovedUNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus, Cardiovascular Disease
Trial Timeline
Sep 1, 2008 → Dec 1, 2018
NCT ID
NCT00700856About add-on pioglitazone + add-on sulphonylurea
add-on pioglitazone + add-on sulphonylurea is a approved stage product being developed by AMD Biotech for Type 2 Diabetes Mellitus. The current trial status is unknown. This product is registered under clinical trial identifier NCT00700856. Target conditions include Type 2 Diabetes Mellitus, Cardiovascular Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00700856 | Approved | UNKNOWN |
Competing Products
20 competing products in Type 2 Diabetes Mellitus